Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3606134 | 0.99 | SMN1; SMN2 (0.31) | SMN1; SMN2ACHEBCHEMAPTNPC1 | |
| SCHEMBL3597898 | 0.92 | NPC1 (0.35) | SMN1; SMN2ACHEBCHEMAPTNPC1 | |
| SCHEMBL3597180 | 0.91 | MAPT (0.34) | ACHEBCHEMAPTNPC1GAA | |
| SCHEMBL3601517 | 0.82 | NPC1 (0.36) | SMN1; SMN2MAPTNPC1GAAATM | |
| SCHEMBL3592666 | 0.82 | NPC1 (0.36) | SMN1; SMN2MAPTNPC1GAAATM | |
| SCHEMBL3595468 | 0.80 | MAPT (0.34) | ACHEBCHEMAPTNPC1GAA | |
| Hydrochloric Acid SCHEMBL3601670 | 0.76 | MAPT (0.36) | SMN1; SMN2ACHEMAPTNPC1GAA | |
| SCHEMBL3593134 | 0.76 | MAPT (0.40) | SMN1; SMN2MAPTNPC1GAAATM | |
| SCHEMBL3598724 | 0.73 | NPC1 (0.39) | SMN1; SMN2MAPTNPC1GAAATM | |
| Hydrochloric Acid SCHEMBL3596333 | 0.72 | NPC1 (0.39) | SMN1; SMN2MAPTNPC1GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803811-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | US | disclosed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | disclosed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | FGFR3, FGFR1, NTRK3 | SMN1; SMN2 3745/4885ACHE 4222/4885BCHE 1443/4885 |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | FGF2, FGF1, FGFR1 | SMN1; SMN2 4602/4885ACHE 4333/4885BCHE 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.